Filtered By:
Drug: Docetaxel
Countries: Japan Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 35 results found since Jan 2013.
Surgical treatment strategies for pancreatic cancer with simultaneous liver metastasis
Conclusion: For highly selective patients with sLMPC who achieve partial response after receiving effective systemic treatment,the adoption of an aggressive surgical treatment strategy can significantly improve survival time;however, surgery dose not provide such survival benefits in patients who do not achieve partial response after systemic chemotherapy.PMID:37402686 | DOI:10.3760/cma.j.cn112139-20230329-00125
Source: Cancer Control - July 4, 2023 Category: Cancer & Oncology Authors: J Huang Z Y Yang R L Wei A T Y A H Atyah Y L Sun L Xu W Y Zhou Source Type: research
Efficacy of chemotherapies for unresectable extramammary Paget disease: a single-centre retrospective study
CONCLUSIONS: Further investigations with prospective analysis are required to confirm these findings.PMID:37162010 | DOI:10.1093/ced/llad172
Source: Cancer Control - May 10, 2023 Category: Cancer & Oncology Authors: Shogo Wada Dai Ogata Eiji Nakano Kenjiro Namikawa Naoya Yamazaki Source Type: research
Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial
CONCLUSION: No clinical concerns were identified with DOC/RAM for NSCLC with brain metastases in this study. Further investigation with a larger sample size is needed to determine the tolerability and safety of these populations (Trial Identifiers: University Hospital Medical Information Network in Japan [UMIN000024551] and Japan Registry of Clinical Trials [jRCTs071180048]).PMID:37053467 | DOI:10.1093/oncolo/oyad013
Source: The Oncologist - April 13, 2023 Category: Cancer & Oncology Authors: Keiko Tanimura Junji Uchino Hideharu Kimura Osamu Hiranuma Yusuke Chihara Shigeru Tanzawa Chieko Takumi Toshiyuki Kita Koji Inoue Koichi Minato Shinnosuke Takemoto Akira Nakao Kenichi Yoshimura Koichi Takayama Source Type: research
Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)
The objective response rate for RD was 28.8% (95% confidence interval [CI], 23.7-34.4). The disease control rate was 69.8% (95% CI, 64.1-75.0).The median progression free survival and overall survival were 4.1 months (95% CI, 3.5-4.6) and 11.6 months (95% CI, 9.9-13.9), respectively. In a multivariate analysis, non-AC and PS 2-3 were independent prognostic factors for worse progression free survival , while bone metastasis on diagnosis, PS 2-3 and non-AC were identified as independent prognostic factors for poor overall survival.INTERPRETATION: RD is a feasible second-line treatment in patients with advanced NSCLC who had ...
Source: Cancer Control - March 11, 2023 Category: Cancer & Oncology Authors: Atsushi Nakamura Ou Yamaguchi Keita Mori Keita Miura Motohiro Tamiya Tomohiro Oba Noriko Yanagitani Hideaki Mizutani Takashi Ninomiya Tomosue Kajiwara Kentaro Ito Akihiko Miyanaga Daisuke Arai Hiroaki Kodama Kunihiko Kobayashi Kyoichi Kaira Source Type: research
Analysis of drug-induced hand-foot syndrome using a spontaneous reporting system database
Conclusion: These findings are crucial for improving the management of the adverse effects caused by anticancer drugs.PMID:35646307 | PMC:PMC9136434 | DOI:10.1177/20420986221101963
Source: Adv Data - June 1, 2022 Category: Epidemiology Authors: Yu Yoshida Sayaka Sasaoka Mizuki Tanaka Kiyoka Matsumoto Misaki Inoue Riko Satake Kazuyo Shimada Ririka Mukai Takaaki Suzuki Mari Iwata Fumiya Goto Takayuki Mori Koki Mori Tomoaki Yoshimura Mitsuhiro Nakamura Source Type: research
Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan
CONCLUSION: Real-world mCRPC treatment patterns largely reflected national guidelines. It is expected that guidelines and treatment patterns will change with the development of new treatment options.PMID:35316501 | DOI:10.1007/s12325-022-02073-w
Source: Adv Data - March 22, 2022 Category: Epidemiology Authors: Andrea Leith Jeri Kim Amanda Ribbands Emily Clayton Lingfeng Yang Sameer R Ghate Source Type: research
A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases
CONCLUSION: TAS-115 appears to demonstrate anti-tumor activity and acceptable tolerability in CRPC patients with bone metastases.PMID:34493431 | DOI:10.1016/j.clgc.2021.07.013
Source: Clinical Genitourinary Cancer - September 8, 2021 Category: Cancer & Oncology Authors: Nobuaki Matsubara Hirotsugu Uemura Satoshi Nagamori Hiroyoshi Suzuki Hiroji Uemura Go Kimura Source Type: research
